Key Drivers
- Strong cash generation
- Heavy debt burden
- Thin net margin
AIAI Summary
Amneal is pivoting from low‑margin generics to higher‑margin biosimilars and specialty launches—supported by improving adjusted EBITDA, FCF and refinancing—but the investment thesis is binary: CREXONT/biosimilar commercialization and manufacturing scale must succeed to justify upside. Investors should only add if they have high conviction that launches will de‑risk leverage toward sub‑3x; otherwise elevated multiples and heavy debt leave the stock exposed to sharp downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash generation
- •Heavy debt burden
- •Thin net margin
AMRX generates strong operating cash flow and healthy gross/EBITDA margins but is heavily levered with negative equity, squeezing net margins and leaving valuation looking demanding.
Price Behavior
Key Price Behavior Insights:
- •Clear downtrend
- •Broken resistance
- •Support at $11.83
Over the last month AMRX fell roughly 18% from about $14.50 to $11.83, breaking near-term resistance around $14.4–$14.9, establishing support near $11.83, and showing accelerating downside momentum that raises short-term risk while offering a lower-entry mean-reversion opportunity.
~11% drop from 2026-03-10 to 2026-03-20 indicating accelerating downside
Sentiment & News
Key News Insights:
- •Beat estimates
- •Margin upside
- •FDA Parkinson's risk
Amneal beat 2025/Q4 estimates, reduced leverage and is guiding modest 2026 revenue with materially higher margin and earnings expansion driven by complex launches, biosimilars and GLP‑1 manufacturing while analyst sentiment is constructive and FDA Parkinson's label scrutiny is a potential sector risk.
Positive operational momentum and deleveraging support upside to earnings and valuation, but watch Parkinson's-label regulatory risk for potential exposure
Similar Companies in Healthcare
Other companies in the same sector with AI ratings